Hyperuricemia:Bempedoic acid, a component of NEXLIZET and NEXLETOL, may increase blood uric acid levels, which may lead to gout. Hyperuricemia may occur early in treatment and persist throughout treatment, returning to baseline following discontinuation of treatment. Assess uric acid levels periodically...
Pharma Grade Bempedoic Acid Market Size And Forecast Pharma Grade Bempedoic Acid Market size was valued at USD 1.2 Billion in 2023 and is projected to reachUSD 3.5 Billion by 2031,growing at aCAGR of 14.33%during the forecast period 2024-2031. ...
Objective Bempedoic acid (BemA; ETC-1002) is a novel drug that targets hepatic ATP-citrate lyase to reduce cholesterol biosynthesis. In phase 2 studies, BemA lowers elevated low-density lipoprotein cholesterol (LDL-C) in hypercholesterolemic patients. In the present study, we tested the ability ...
Bempedoic acid is being evaluated as a potential treatment for hyperlipidemia in pediatric populations. An initial phase 2 study in children aged 6–17 years with heterozygous familial hypercholesterolemia (HeFH) was designed to evaluate the PK, pharmacodynamics, and safety of bempedoic acid (NCT0569426...